Alto Neuroscience initiates Phase 2b trial of ALTO-207 in treatment-resistant depression

Alto Neuroscience, Inc.

Alto Neuroscience, Inc.

ANRO

0.00
  • Alto Neuroscience initiated Phase 2b randomized, double-blind, placebo-controlled trial of ALTO-207 as adjunctive treatment for adults with treatment-resistant depression in first quarter 2026, positioning program for a potential registrational pathway.
  • Trial will test whether ALTO-207 can replicate antidepressant benefits seen previously with pramipexole, with topline results expected in 2H 2027.
  • Separate Phase 2 proof-of-concept results for ALTO-101 in cognitive impairment associated with schizophrenia were already presented, missing primary biomarker endpoint while showing signals consistent with potential benefits on broader cognition and attention measures.
  • Cash, cash equivalents, and restricted cash totaled USD 264.2 million at March 31, 2026, following USD 120 million PIPE financing, with runway expected through 2029 including planned ALTO-207 Phase 3 start in early 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605130703BIZWIRE_USPR_____20260513_BW295402) on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.